Journal ArticleDOI
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Reads0
Chats0
About:
This article is published in Yearbook of Oncology.The article was published on 2010-01-01. It has received 850 citations till now. The article focuses on the topics: Dasatinib & Imatinib.read more
Citations
More filters
Journal ArticleDOI
The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group.
Noriyoshi Iriyama,Kazuteru Ohashi,Satoshi Hashino,Shinya Kimura,Chiaki Nakaseko,Hina Takano,Masayuki Hino,Michihiro Uchiyama,Satoshi Morita,Junichi Sakamoto,Hisashi Sakamaki,Koiti Inokuchi +11 more
TL;DR: Low-dose dasatinib can attain MMR and DMR without severe toxicity in patients with CML-CP who are unable to achieve MMR with low-dose imatinib, especially if they are otherwise considering a cessation of treatment.
Journal ArticleDOI
Impact of imatinib interruption and duration of prior hydroxyurea on the treatment outcome in patients with chronic myeloid leukemia: Single institution experience.
Wael Edesa,Raafat Abdel-Malek +1 more
TL;DR: Patients regular on imatinib had statistically significant difference with respect to major molecular response, complete molecular response and progression free survival compared to those who had periods of drug interruption, thus more governmental support is needed to supply the drug without interruption to improve the outcome of therapy.
Aberrant kinase activation as a therapy target : Chronic myeloid leukemia as a model disease
TL;DR: The next generation of scientists and broadcasters will be able to assess the importance of human interaction with the natural world and provide real-time information about natural disasters.
Journal ArticleDOI
Selection of therapy: rational decisions based on molecular events.
TL;DR: To what extent molecular data can be used to rationalize therapeutic choices in the treatment of chronic myeloid leukemia is reviewed, focusing on biomarkers that do not reflect disease burden as a surrogate of responsiveness to treatment.
Journal ArticleDOI
Insights into the management of chronic myeloid leukemia in resource-poor settings: a Mexican perspective.
Andrés Gómez-De-León,David Gómez-Almaguer,Guillermo J. Ruiz-Delgado,Guillermo J. Ruiz-Argüelles +3 more
TL;DR: This review aims to provide an insight into the management of patients with CML living in a resource-limited setting by addressing several issues: diagnosis, initial treatment, disease monitoring, and additional treatment alternatives including allogeneic hematopoietic stem cell transplantation.
References
More filters
Journal ArticleDOI
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
Hagop M. Kantarjian,Neil P. Shah,Andreas Hochhaus,Jorge E. Cortes,Sandip Shah,Manuel Ayala,Beatriz Moiraghi,Zhixiang Shen,Jiri Mayer,Ricardo Pasquini,Hirohisa Nakamae,Françoise Huguet,Concepción Boqué,Charles Chuah,Eric Bleickardt,M. Brigid Bradley-Garelik,Chao Zhu,Ted Szatrowski,David Shapiro,Michele Baccarani +19 more
TL;DR: Since achieving complete cytogenetic response within 12 months has been associated with better long-term, progression-free survival, dasatinib may improve the long- term outcomes among patients with newly diagnosed chronic-phase CML.